Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial
PLOS One · 13.08.2026 · 21 (8) · e0356180
DOI: 10.1371/journal.pone.0356180 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift PLOS One, online erschienen am 13.08.2026. Verfasst von Koki Nambu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Oral and Maxillofacial Surgery, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, …. Hauptthemen laut MEDLINE: Dietary Supplements, Gastrointestinal Microbiome, Inulin, Lichen Planus, Oral. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency, Takeda Science Foundation.
Abstract (Originalsprache)
Oral lichen planus is a chronic inflammatory disease of the oral mucosa characterised by immune dysregulation, but its pathogenesis remains incompletely understood and no curative treatment has been established. Our previous work showed that patients with oral lichen planus exhibit gut dysbiosis, including reduced microbial diversity and depletion of butyrate-producing bacteria. Because butyrate promotes regulatory T-cell differentiation and supports immune homeostasis, targeting this dysbiosis may represent a microbiota-directed approach for immune modulation in oral lichen planus. This study aims to investigate the effects of inulin supplementation on the gut microbiota and related immune markers in patients with oral lichen planus. This multicentre, double-blind, randomised, placebo-controlled parallel-group trial will enrol 80 patients with oral lichen planus. Participants will be randomly assigned in a 1:1 ratio to receive either inulin (8 g/day) or a maltose placebo for 4 weeks, in addition to standard care. The primary outcome is the change in the relative abundance of prespecified butyrate-producing gut bacteria from baseline to the end of intervention at Week 6. Secondary outcomes include changes in gut microbiota diversity, salivary microbiota composition, faecal short-chain fatty acid concentrations, peripheral blood regulatory T-cell counts, blood test parameters, and clinical symptoms of oral lichen planus. Analyses will follow the intention-to-treat principle, and between-group differences will be assessed using appropriate statistical methods. This trial is designed to evaluate, in a randomised placebo-controlled setting, whether a microbiota-directed intervention can modify gut microbial profiles and related immune markers in patients with oral lichen planus. The findings are expected to clarify whether inulin supplementation can modify gut microbial profiles and related immunological markers in patients with oral lichen planus. Trial registration: UMIN Clinical Trials Registry (UMIN-CTR), UMIN000060840, registered on 1 April 2026 ( https://rctportal.mhlw.go.jp/detail/um?trial_id=UMIN000060840# ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Oral and Maxillofacial Surgery, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
- OBT Research Center, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
- Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.
- Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Pediatrics, Kansai Medical University, Osaka, Japan.
ORCID-Profile: Koki Nambu, Naoki Kaneko, Eiji Iwata
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Takeda Science Foundation
- Kaibara Morikazu Medical Science Promotion Foundation
Zitieren
APA
Nambu, K., Kaneko, N., Yokomizo, S., Chen, H., Yan, L., Shiyao, W., Shizuma, R., Iwata, E., Ohyama, Y., Akagawa, S., Ibaragi, S., Kawano, S., & Moriyama, M. (2026). Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial. PLOS One, 21(8), e0356180. https://doi.org/10.1371/journal.pone.0356180
Vancouver
Nambu K, Kaneko N, Yokomizo S, Chen H, Yan L, Shiyao W, et al. Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial. PLOS One. 2026;21(8):e0356180. doi:10.1371/journal.pone.0356180
BibTeX
@article{Nambu2026,
author = {Nambu, Koki and Kaneko, Naoki and Yokomizo, Shiho and Chen, Hu and Yan, Lijing and Shiyao, Wang and Shizuma, Ryusei and Iwata, Eiji and Ohyama, Yukiko and Akagawa, Shohei and Ibaragi, Soichiro and Kawano, Shintaro and Moriyama, Masafumi},
title = {Study protocol: Effect of inulin supplementation on gut microbiota in patients with oral lichen planus — A double-blind, randomised, placebo-controlled parallel-group trial},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0356180},
doi = {10.1371/journal.pone.0356180}
}
EUVIMED